Active, Not Recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051
- Conditions
- AML, Disease Attributes, Hematologic Diseases, +10 more
- Locations
-
- CHU d'Amiens Amiens, France
- CHU d'Angers Angers, France
- CHU Bordeaux Bordeaux, France
- CHU de Caen Caen, France